Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
The U.S. stock market experienced a notable downturn today, November 6, 2025, as investors grappled with growing apprehension over the lofty valuations of artificial intelligence (AI) stocks and a significantly deteriorating job market. Major indices, including the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average, registered sharp
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as the linchpin in the quest to develop cures for a myriad of debilitating diseases. This significant investment is poised to revolutionize how scientists approach genetic disorders, moving beyond [...]
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest trading volume and driving market activity.
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,
As November 2025 unfolds, the global stock markets find themselves at a critical juncture, struggling to reclaim the robust bullish momentum that characterized much of the preceding years. A palpable shift in investor sentiment is emerging, with an increasing number of market participants questioning the lofty valuations, particularly within the
Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.67 per share was 8.5% above analysts’ consensus estimates.
Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.
The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in turn, significantly bolstered the US Dollar, pushing it to multi-month highs against a basket of major currencies. The immediate implication for
Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk.
The financial markets, still reeling from a tumultuous period marked by significant downturns, are now grappling with an uneasy attempt at consolidation. As of November 5, 2025, investors are witnessing a landscape fundamentally altered by a series of sharp slides, most notably the tariff-induced crash of April 2025 and a
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo Nordisk (NYSE: NVO), a pioneer in the space with its blockbuster drugs Wegovy and Ozempic, has experienced a tumultuous year, seeing
The United States finds itself in an unprecedented economic fog as a prolonged government shutdown, now stretching well into its second month, has brought the flow of critical official data to a grinding halt. With federal agencies responsible for collecting and disseminating vital economic indicators largely shuttered, policymakers, businesses, and
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Wednesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Washington D.C., November 5, 2025 – The United States is grappling with an unprecedented fiscal crisis, as an ongoing government shutdown, now in its 36th day, has officially become the longest in the nation's history. This prolonged political impasse, rooted in fierce partisan disagreements over federal spending and policy riders,
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD) has successfully leveraged AI to design antibodies from scratch, achieving unprecedented atomic precision. This groundbreaking development, primarily driven by a sophisticated generative AI model [...]
